Regencell Bioscience (NASDAQ:RGC) Stock Price Up 8.8% – Should You Buy?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) traded up 8.8% during mid-day trading on Friday . The stock traded as high as $28.40 and last traded at $29.2770. 36,687 shares were traded during trading, a decline of 88% from the average session volume of 318,715 shares. The stock had previously closed at $26.91.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Regencell Bioscience Stock Up 6.1%

The stock’s fifty day moving average price is $27.34 and its 200 day moving average price is $24.25.

Regencell Bioscience (NASDAQ:RGC) last issued its earnings results on Friday, May 8th. The company reported $0.00 earnings per share for the quarter.

Institutional Trading of Regencell Bioscience

A number of institutional investors have recently modified their holdings of the company. Seven Fleet Capital Management LP bought a new stake in shares of Regencell Bioscience in the 4th quarter valued at about $92,000. Vident Advisory LLC boosted its holdings in shares of Regencell Bioscience by 65.7% in the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after buying an additional 11,866 shares in the last quarter. Hudson Bay Capital Management LP bought a new stake in shares of Regencell Bioscience in the 4th quarter valued at about $275,000. XTX Topco Ltd bought a new stake in shares of Regencell Bioscience in the 3rd quarter valued at about $598,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Regencell Bioscience in the 2nd quarter valued at about $768,000. 0.13% of the stock is currently owned by institutional investors.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.